Please assess the completion status of the following clinical trial:

Trial Title: Rapid Antidepressant Effects of Ketamine in Major Depression

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
* INCLUSION CRITERIA:~General patient inclusion criteria~1. Male or female subjects, 18 to 65 years of age.~2. Each subject must have a level of understanding sufficient to agree to all required tests and examinations and sign an informed consent document.~3. Subjects must fulfill DSM-IV criteria for Major Depressive Disorder (MDD) without psychotic features, based on clinical assessment and confirmed by a structured diagnostic interview, SCID-P.~4. Subjects must have an initial score of at least 20 on the MADRS at screen and at baseline of study phase I.~5. Subjects must have failed to respond in the past to an adequate dose and duration of at least one antidepressant (SSRI, bupropion, or venlafaxine) during a depressive episode~6. Current depressive episode of at least 4 weeks duration.~Additional inclusion criteria for substudy 4 (patients with MDD)~1. Age of onset less than 40 years of age.~2. Subjects with MDD must fulfill DSM-IV criteria for Major Depression single episode or recurrent without psychotic features based on clinical assessment and confirmed by a structured diagnostic interview (SCID-P).~3. A failed adequate trial of ECT would count as an adequate antidepressant trial.~4. In women of childbearing age, a negative pregnancy test within 24 hours of MRI.~Inclusion criteria for healthy control subjects (Substudy 4 only)~1. Age 18-65 years.~2. Written informed consent completed.~EXCLUSION CRITERIA:~General patient exclusion criteria~1. Current or past diagnosis of Schizophrenia or any other psychotic disorder as defined in the DSM-IV.~2. Subjects with a history of DSM-IV drug or alcohol dependency or abuse (except for nicotine or caffeine) within the preceding 3 months.~3. Female subjects who are either pregnant or nursing.~4. Serious, unstable illnesses including hepatic, renal, gastroenterologic, respiratory, cardiovascular (including ischemic heart disease), endocrinologic, neurologic, immunologic, or hematologic disease.~5. Subjects with uncorrected hypothyroidism or hyperthyroidism.~6. Subjects with one or more seizures without a clear and resolved etiology.~7. Treatment with a reversible MAOI within 4 weeks prior to study phase I.~8. Treatment with fluoxetine within 5 weeks prior to study phase I.~9. Treatment with any other concomitant medication not allowed (Appendix A for Substudy 2; Appendix G for Substudy 4) 14 days prior to study phase I.~10. No structured psychotherapy will be permitted during the study.~11. Current NIMH employee/staff or their immediate family member.~Additional Exclusion Criteria for substudy 2 (patients with MDD)~1. Previous treatment with ketamine or hypersensitivity to amantadine.~Additional Exclusion Criteria for Substudy 4 (patients with MDD)~1. Subjects who currently are using drugs (except for caffeine or nicotine), must not have used illicit substances in the 2 weeks prior to screen and must have a negative alcohol and drug urine test (except for prescribed benzodiazepines) urine test at screening.~2. Presence of any medical illness likely to alter brain morphology and/or physiology (e.g., hypertension, diabetes) even if controlled by medications.~3. Clinically significant abnormal laboratory tests.~4. For imaging procedures, Presence of metallic (ferromagnetic) implants (e.g, heart pacemaker, aneurysm clip).~5. Subjects who, in the investigator's judgment, pose a current serious suicidal or homicidal risk, or who have a MADRS item 10 score of \>4.~Exclusion Criteria for healthy control subjects (Substudy 4 only)~1. Current or past Axis I diagnosis~2. Presence of metallic (ferromagnetic) implants (e.g., heart pacemaker, aneurysm clips).~3. Presence of medical illness likely to alter brain morphology and/or physiology (e.g., hypertension, diabetes) even if controlled by medications.~4. Treatment with any of the exclusionary medications detailed in Appendix G 14 days prior to Phase 1 of the Substudy 4.~5. Current or past alcohol or substance abuse or dependence diagnosis (except for nicotine or caffeine).~6. Presence of psychiatric disorders in first-degree relatives.~7. Female subjects who are either pregnant or nursing.~7.8.Current NIMH employee/staff or their immediate family member.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Ketamine, Then Placebo (Type: EXPERIMENTAL): Ketamine and placebo infusions were administered two weeks apart, with Ketamine's dose being 0.5 mg/kg.
- Placebo, Then Ketamine (Type: EXPERIMENTAL): Placebo and Ketamine infusions were administered two weeks apart, with Ketamine's dose being 0.5 mg/kg

Based on this trial design, predict the completion outcome and termination type (if applicable).